CytomX Therapeutics, Inc.

Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.

CTMX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://cytomx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CytomX Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
$AMARIN CORP PLC\UK Logo$	AMARIN CORP PLC\UK Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.	United States of America	AMRN
	AMGEN INC Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.	United States of America	AMGN
	Amicogen, Inc. Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.	South Korea	092040
	AMICUS THERAPEUTICS, INC. Develops advanced therapies for rare lysosomal storage disorders.	United States of America	FOLD
	AMINOLOGICS CO.,LTD. Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.	South Korea	074430
	Amneal Pharmaceuticals, Inc. Develops & commercializes essential medicines: generics, injectables & specialty drugs.	United States of America	AMRX
	Amphastar Pharmaceuticals, Inc. Develops and manufactures complex injectable, intranasal, and inhalation pharmaceutical products.	United States of America	AMPH
	Amylyx Pharmaceuticals, Inc. Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.	United States of America	AMLX
	AN2 Therapeutics, Inc. Developing novel small molecule drugs for infectious diseases and oncology using boron chemistry.	United States of America	ANTX
	Ananda Pharma Plc Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.	United Kingdom	ANAN